Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate

Blood. 2020 Nov 5;136(19):2229-2232. doi: 10.1182/blood.2020006048.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Multicenter Study
  • Research Support, N.I.H., Intramural
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Antiretroviral Therapy, Highly Active / methods*
  • Central Nervous System Neoplasms / drug therapy*
  • Central Nervous System Neoplasms / pathology
  • Central Nervous System Neoplasms / virology
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • HIV / isolation & purification
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • HIV Infections / virology
  • Humans
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Lymphoma, Non-Hodgkin / pathology
  • Lymphoma, Non-Hodgkin / virology
  • Male
  • Methotrexate / administration & dosage
  • Middle Aged
  • Prognosis
  • Prospective Studies
  • Rituximab / administration & dosage
  • Survival Rate

Substances

  • Rituximab
  • Methotrexate